MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer.

Justyna Magdalena Hermanowicz Krystyna Pawlak Beata Sieklucka Robert Czarnomysy Iwona KwiatkowskaAdam KazberukArkadiusz SurazynskiMariusz MojzychDariusz Pawlak

Published in: Cancers (2021)

A novel 1,2,4-triazine derivative with a dual mechanism of antitumor activity-MM-129, may act as a chemosensitizer, overcoming chemoresistance against 5-FU, the first-line agent in the chemotherapy of colon cancer.

Keyphrases

cancer therapy
locally advanced
water soluble
drug delivery
mass spectrometry
cancer stem cells
chemotherapy induced